CompoAtlas

GUMMYFITS - GOMMES DE GESTION DU POIDS

Food supplement declared in France, declaration No 2021-3-251, decision dated 3 March 2021

GUMMYFITS - GOMMES DE GESTION DU POIDS (Prozis) is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Glucomannane. None of the rules we check flags an issue with its declared composition.

Brand
Prozis
Food business operator placing the product on the market
Prozis.Com, S.A.
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Gummy
Daily dose
6 gommes (2 gommes 3 fois)
Directions for use
Ingérer 2 gommes 3 fois par jour avec 1 ou 2 verres d'eau. Prendre dans le cadre d'un régime hypocal
Intended populations
Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Children (under 12), Young children (aged 1 to 3), Infants (under 1 year), Taking medication
Objectives stated by the manufacturer (these are not authorised claims)
Slimming / Appetite control
Flavourings
Fraise

Declaration 222699, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Other active ingredients

NamePer day
Glucomannanenot declared

Additives

E965, E330, E903, E120, E163

Other ingredients

gélatine, huile de noix de coco fractionnée, huile de palme

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Utilisation réservée aux adultes. L’effet bénéfique est obtenu avec une dose journalière de 3 g de glucomannane en trois doses de 1 g à prendre avec 1 à 2 verres d’eau, avant les repas et dans le cadre d’un régime hypocalorique. Une consommation excessive peut causer?des effets laxatifs. Ce produit peut présenter un risque d’étouffement pour les personnes ayant des difficultés à avaler ou lorsqu’il est?ingéré avec une quantité insuffisante de liquide. Boire beaucoup d'eau afin de s'assurer que le produit atteigne l'estomac. Ne pas prendre immédiatement avant le coucher. Éviter de prendre ce produit avec des médicaments et autres compléments alimentaires à base de fibres. Si vous êtes diabétique, consultez votre médecin avant de prendre ce produit. À utiliser dans le cadre d'un régime hypocalorique adapté, d'un mode de vie sain et d'une activité physique régulière. Il est recommandé de consulter votre médecin si vous prenez ce produit pendant plus de trois semaines.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Glucomannane
    Read the warning, when it applies and the studies cited

    GLUCOMANNAN

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (FDA 2023).

    Sources cited by Health Canada (1)
    • FDA 2023: United States Food and Drug Administration. Specific Labeling Requirements for Specific Drug Products. Code of Federal Regulations Title 21, Volume 4 (21CFR201.319). Rockville (MD): United States Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2023 December 31]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.319

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (UpToDate 2023; EMA 2013; Chen et al. 2003; Vuksan et al. 2001).

    Sources cited by Health Canada (4)
    • Chen HL, Sheu WH, Tai TS, Liaw YP, Chen YC. 2003. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects—a randomized double-blind trial. Journal of American College of Nutrition 22(1):36-42.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf
    • UpToDate 2023: Wolters Kluwer. [Accessed 2023 December 31]. Available from: https://www.wolterskluwer.com/en/solutions/uptodate
    • Vuksan V, Sievenpiper JL, Xu Z, Wong EYY, Jenkins AL, Beljan-Zdravkovic U, Leiter LA, Josse RG, Stavro M.P. 2001. Konjac-mannan and American ginsing: emerging alternative therapies for type 2 diabetes mellitus. Journal of the American College of Nutrition 20:370S-380S.

    Condition of application: Laxative; Promotion of bowel movement; Constipation relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).

    Sources cited by Health Canada (2)
    • Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.
    • Repchinsky C, editor. 2002. Patient Self-Care. Helping Patients Make Therapeutic Choices. Ottawa (ON): Canadian Pharmacists Association.

    Contraindications

    Condition of application: All products.

    Do not use if you have difficulty swallowing (FDA 2023; Sweetman 2007; Vanderbeek et al. 2007; Henry et al. 1986).

    Sources cited by Health Canada (5)
    • FDA 2023: United States Food and Drug Administration. Specific Labeling Requirements for Specific Drug Products. Code of Federal Regulations Title 21, Volume 4 (21CFR201.319). Rockville (MD): United States Department of Health and Human Services, U.S. Food and Drug Administration. [Accessed 2023 December 31]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.319
    • Henry DA, Mitchell AS, Aylward J. 1986. Glucomannan and risk of esophageal obstruction. British Medical Journal 292:591-592.
    • Sweetman SC, editor. 2007. Martindale: The Complete Drug Reference, 35th edition. London (GB): Pharmaceutical Press.
    • Vanderbeek PB, Fasano C, O'Malley G, Hornstein J. 2007. Esophageal obstruction from a pharmacobezoar containing glucomannan. Clinical Toxicology 45(1):80-82.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Consulté le 31 décembre 2023]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2013; Pray 2006; Berardi et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. 2002. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association.
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf
    • Pray WS. 2006. Non-Prescription Product Therapeutics, 2nd edition. New York (NY): Lippincott Williams & Wilkins.

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2013).

    Sources cited by Health Canada (1)
    • EMA 2013. European Medicines Agency. Final Community Herbal Monograph on Plantago afra L. et Plantago indica L., semen. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 14 May 2013. [Accessed 2023 December 31]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-afra-l-et-plantago-indica-l-semen_en.pdf

    When using this product you may experience temporary gas and bloating (Sood et al. 2008).

    Sources cited by Health Canada (1)
    • Sood N, Baker WL, Coleman CI. 2008. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. American Journal of Clinical Nutrition 88(4):1167-1175.

    Health Canada monograph dated 26 July 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Prozis

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “GUMMYFITS - GOMMES DE GESTION DU POIDS (Prozis): composition and regulation”, https://compoatlas.com/en/supplements/products/222699-gummyfits-gommes-de-gestion-du-poids, updated 15 November 2026.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line